Table 1.
Baseline characteristics of participants
| Characteristics | MSCs group (N = 15) | Placebo group (N = 15) |
|---|---|---|
| Age (years) | 67.27 ± 5.23 | 69.27 ± 5.02 |
| Sex (n, %) | ||
| Male | 5 (33.33) | 7 (46.67) |
| Female | 10 (66.67) | 8 (53.33) |
| BMI (kg/m2) | 24.03 ± 2.89 | 24.95 ± 3.67 |
| Fried frailty phenotype scale | 2 (2, 2) | 2 (2, 3) |
| Chronic conditions | ||
| Hypertension (%) | 4 (26.67) | 7 (46.67) |
| Dyslipidemia (%) | 4 (46.67) | 1 (6.67) |
| Type 2 diabetes mellitus (%) | 3 (20) | 5 (33.33) |
| Ischemic cardiomyopathy (%) | 2 (13.33) | 2 (13.33) |
| Medication | ||
| Aspirin (%) | 2 (13.33) | 1 (6.67) |
| ACEI/ARB (%) | 2 (13.33) | 4 (26.67) |
| Calcium antagonists (%) | 2 (13.33) | 1 (6.67) |
| Metformin (%) | 1 (6.67) | 2 (13.33) |
| Other oral antidiabetics (%) | 2 (13.33) | 3 (20) |
| Insulin (%) | 2 (13.33) | 2 (13.33) |
| Stain (%) | 5 (33.33) | 1 (6.67) |
| Laboratory | ||
| Hemoglobin (g/L) | 135.80 ± 7.72 | 132.47 ± 13.71 |
| White blood cell count (109/L) | 5.89 ± 1.37 | 5.69 ± 1.45 |
| Platelet count (109/L) | 203.2 ± 42.75 | 206.4 ± 73.50 |
| AST (U/L) | 23.07 ± 14.26 | 23.73 ± 8.68 |
| ALT (U/L) | 22.73 ± 18.18 | 21.00 ± 12.62 |
| GFR (mL/min per 1.73 m2) | 70.73 ± 13.98 | 75.93 ± 16.35 |
| FBG (mmol/L) | 5.94 ± 1.41 | 5.89 ± 1.26 |
Data are median (interquartile range, IQR), mean (standard deviation, SD), or n (%)